Abcuro is developing a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to target key compartments of the immune system. Abcuro was launched in 2016 and to date it has raised over $12M to advance two functionally differentiated therapeutic programs that target KLRG1, an inhibitory receptor on T and NK cells. Abcuro’s autoimmunity program is under development for inclusion body myositis (IBM), primary biliary cholangitis (PBC) and other T cell driven autoimmunity indications. Abcuro's immuno-oncology program is being developed for solid tumors via a biomarker based indication selection strategy. Both programs have completed candidate selection and are now in pre-clinical development.